Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome
Soichiro Minami(Sendai Kousei Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Shin Saito(Shizuoka Cancer Center), Shuichiro Hara(Yamagata University), Tomoiki Aiba(Sendai Kousei Hospital), Yusuke Yamazaki(Sendai Kousei Hospital), Yosuke Kawashima(Sendai Kousei Hospital), Tsuyoshi Doman(Sendai Kousei Hospital), Shinsuke Yamanda(Sendai Kousei Hospital), Tetsuo Odaka(Sendai Kousei Hospital), Takahiro Ogasawara(Sendai Kousei Hospital), Masahiro Matsuno(Sendai Kousei Hospital), Yuichiro Kimura(Tohoku University), Yukihiro Toi(Sendai Kousei Hospital), Hisashi Shimizu, Yasuhiko Munakata(Tohoku University), Jun Sugisaka(Sendai Kousei Hospital)
Cited by 3
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695